文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

作者信息

Zhang Hua, Snyder Kristen M, Suhoski Megan M, Maus Marcela V, Kapoor Veena, June Carl H, Mackall Crystal L

机构信息

Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

出版信息

J Immunol. 2007 Oct 1;179(7):4910-8. doi: 10.4049/jimmunol.179.7.4910.


DOI:10.4049/jimmunol.179.7.4910
PMID:17878391
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3809056/
Abstract

Artificial APCs (aAPCs) genetically modified to express selective costimulatory molecules provide a reproducible, cost-effective, and convenient method for polyclonal and Ag-specific expansion of human T cells for adoptive immunotherapy. Among the variety of aAPCs that have been studied, acellular beads expressing anti-CD3/anti-CD28 efficiently expand CD4+ cells, but not CD8+ T cells. Cell-based aAPCs can effectively expand cytolytic CD8+ cells, but optimal costimulatory signals have not been defined. 4-1BB, a costimulatory molecule expressed by a minority of resting CD8+ T cells, is transiently up-regulated by all CD8+ T cells following activation. We compared expansion of human cytolytic CD8+ T cells using cell-based aAPCs providing costimulation via 4-1BB vs CD28. Whereas anti-CD3/anti-CD28 aAPCs mostly expand naive cells, anti-CD3/4-1BBL aAPCs preferentially expand memory cells, resulting in superior enrichment of Ag-reactive T cells which recognize previously primed Ags and efficient expansion of electronically sorted CD8+ populations reactive toward viral or self-Ags. Using HLA-A2-Fc fusion proteins linked to 4-1BBL aAPCs, 3-log expansion of Ag-specific CD8+ CTL was induced over 14 days, whereas similar Ag-specific CD8+ T cell expansion did not occur using HLA-A2-Fc/anti-CD28 aAPCs. Furthermore, when compared with cytolytic T cells expanded using CD28 costimulation, CTL expanded using 4-1BB costimulation mediate enhanced cytolytic capacity due, in part, to NKG2D up-regulation. These results demonstrate that 4-1BB costimulation is essential for expanding memory CD8+ T cells ex vivo and is superior to CD28 costimulation for generating Ag-specific products for adoptive cell therapy.

摘要

相似文献

[1]
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

J Immunol. 2007-10-1

[2]
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

J Immunol. 2001-8-1

[3]
Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells ex vivo.

Cell Mol Immunol. 2008-2

[4]
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

J Immunother. 2011-4

[5]
A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.

J Transl Med. 2016-7-19

[6]
Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells.

Blood. 2002-11-1

[7]
Transient stimulation expands superior antitumor T cells for adoptive therapy.

JCI Insight. 2017-1-26

[8]
Tumor expression of 4-1BB ligand sustains tumor lytic T cells.

Cancer Biol Ther. 2003

[9]
Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.

Clin Immunol. 2006-4

[10]
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.

J Immunol. 2004-1-15

引用本文的文献

[1]
The potential of chimeric antigen receptor -T cell therapy for endocrine cancer.

World J Surg Oncol. 2025-4-22

[2]
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.

J Hematol Oncol. 2024-11-5

[3]
High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.

Front Immunol. 2024

[4]
Cancer cell targeting by CAR-T cells: A matter of stemness.

Front Mol Med. 2022-12-13

[5]
Treatment of multiple myeloma: What is the impact on T-cell function?

Ther Adv Hematol. 2024-5-7

[6]
Bridging the gender gap in autoimmunity with T-cell-targeted biomaterials.

Curr Opin Biotechnol. 2024-4

[7]
Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer.

Cancers (Basel). 2024-1-12

[8]
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.

Mil Med Res. 2023-11-8

[9]
Evolution by innovation as a driving force to improve TCR-T therapies.

Front Oncol. 2023-9-21

[10]
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.

J Hematol Oncol. 2023-7-22

本文引用的文献

[1]
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

Mol Ther. 2007-5

[2]
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Nat Med. 2006-10

[3]
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.

Proc Natl Acad Sci U S A. 2006-6-13

[4]
IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival.

J Immunol. 2006-3-1

[5]
Restoring function in exhausted CD8 T cells during chronic viral infection.

Nature. 2006-2-9

[6]
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.

J Immunol. 2005-7-15

[7]
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.

Cancer Res. 2005-6-15

[8]
HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.

Eur J Immunol. 2005-7

[9]
The B7 family revisited.

Annu Rev Immunol. 2005

[10]
Immunology of hepatitis B virus and hepatitis C virus infection.

Nat Rev Immunol. 2005-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索